# A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Source: https://onco.cc/trials/nct04626635/  
OnCo record `nct04626635` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of REGN7075, Cemiplimab, Bevacizumab and Trifluridine/tipiracil in advanced solid tumours, run by Regeneron Pharmaceuticals, active and no longer recruiting.

## Summary

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers is a phase 1/2 interventional study registered as NCT04626635 by Regeneron Pharmaceuticals, with 548 participants enrolled, started 2020-12-21 and due to reach its primary completion in 2026-11-13. Interventions recorded: REGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab and Trifluridine-tipiracil.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04626635
- Phase: 1/2
- Setting: A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 548

## Sources

- ClinicalTrials.gov NCT04626635: https://clinicaltrials.gov/study/NCT04626635

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [REGN7075](https://onco.cc/drugs/regn7075/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct04626635.json